Patent intelligence · US
US 8501713
Drug combinations for the treatment of duchenne muscular dystrophy
Drug combinations for the treatment of duchenne muscular dystrophy
Patent details — US 8501713
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 6, 2013
- Expiration
- Aug 1, 2033
- Applicant
- Summit Corporation Plc
- Claims
- 6
- CPC classes
- A61K, A61K31/423, A61K31/573, A61K45/06
Quick answer
US 8501713 (Drug combinations for the treatment of duchenne muscular dystrophy) is held by Summit Corporation Plc. Status: granted. Granted Aug 6, 2013. Expires Aug 1, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Summit Corporation Plc
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K31/423, A61K31/573, A61K45/06, A61P, A61P21/00
More from Summit Corporation Plc
Related pharmaceutical patents in our USPTO index.
-
US 12318487
Solid tablet dosage form of ridinilazole
granted -
US 11344575
Vascular calcification prevention and treatment
granted -
US 11007171
Treatment and prevention of joint disorders
granted -
US 9763925
Antibacterial compounds
granted -
US 9492433
Pharmaceutical composition for the treatment of Duchenne muscular dystrophy
granted -
US 9314456
Antibacterial compounds
granted -
US 9278091
Compounds for the treatment of Clostridium difficile associated disease
granted -
US 8987308
Compounds for the treatment of Clostridium difficile-associated disease
granted
Frequently asked questions
What is US patent 8501713?
US 8501713 (Drug combinations for the treatment of duchenne muscular dystrophy) is held by Summit Corporation Plc. Status: granted. Granted Aug 6, 2013. Expires Aug 1, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8501713?
Summit Corporation Plc is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.
When does US 8501713 expire?
Our index shows an expiration date of Aug 1, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.